This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

CAMHS won't see you now

Role of prandial glucose regulators

Your article on diabetes care under the new contract (July 28) states that prandial glucose regulators are less effective than a sulphonylurea in lowering HbA1c. In fact repaglinide (NovoNorm)) has been shown to lower fasting glucose by up to 3.6mmol/l and HbA1c by up to 2.3 per cent relative to placebo in sulphonylurea-naive patients (Van Gaal et al, Diabetes Res Clin Pract 53, 2001:141-8).

In terms of maintaining HbA1c repaglinide is equivalent to glibenclamide (Landgraf R et al, Eur J Clin Pharm 1999; 55: 165-171) and gliclazide (data on file, Novo Nordisk study 047) but superior to glipzide (Madsbad S et al, Diabetic Medicine 2001; 18:395-401).

Contrary to creating compliance problems, repaglinide's dosing is intended to make it easy for patients to have a flexible lifestyle, used in a 'one-meal, one-dose; no-meal no-dose' basis up to four times a day.

Dr G Nelson

Senior Medical Adviser

Novo Nordisk, Crawley

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say